On this video, Kelly L. Stratton, MD, FACS, discusses a noteworthy side of a section 1B trial evaluating relugolix (Orgovyx) and enzalutamide (Xtandi) for high-risk prostate most cancers. Stratton is an affiliate professor of urologic oncology on the College of Oklahoma, Oklahoma Metropolis.
Transcription:
What else would you want so as to add about this research?
I feel that basically the truth that that is utterly an oral therapy, it makes it very simple for sufferers to handle and be concerned with so they do not have to return and get photographs. There aren’t any infusions. Sufferers, I feel, actually profit from that and are proud of that potential mixture. And this research is supported by funding by way of the NCCN, and in order that’s a vital component for us. It is made it potential for us to open the research.
This transcription was edited for readability.
